:: Volume 7, Issue 1 (Fedruary-March 2018) ::
JHPM 2018, 7(1): 9-16 Back to browse issues page
Comparison of the Personality Dimensions of Patients with Major Depressive Disorder using Serotonin Reuptake Inhibitors Antidepressant Drugs, with Serotonin Reuptake Inhibitors and Triangular Drugs Combination
Saeed Pournaghash Tehrani , Fatemeh Shahcheraghi
Faculty of Psychology and Education, University of Tehran, Tehran, Iran , Spnaghash@ut.ac.ir
Abstract:   (5362 Views)
Introduction: Neurotransmitter systems, involved in depressive disorders, are in line with personality dimensions. The present study aimed at comparing personality dimensions of individuals with major depressive disorders using Selective Serotonin Reuptake Inhibitors (SSRIs) drugs with those of individuals using Tricyclic Antidepressant (TCA) in combination with SSRIs.
Methods: The present study was descriptive-comparative, which was carried out during year 2017 in two groups of 37 patients with major depressive disorder, who used Selective Serotonin Reuptake Inhibitors (SSRIs) with those of individuals using Tricyclic Antidepressant (TCA) in combination with SSRIs. Samples were selected by the convince sampling method from Baqiyatallah al-Azam hospital, Taleghani, Faculty of Psychology of Tehran University and Sepehr clinics. For data collection, the “Temperament and Character Inventory” (TCI-56) was used. The validity and reliability of this inventory has been confirmed in previous studies. Data were analyzed with the SPSS version 24 software.
Results: The two groups did not differ significantly in terms of personality traits. In other words, the mean personality characteristics did not differ significantly between the two groups (P < 0.01).
Conclusions: According to the results of this study, prescribing both drug groups is recommended to increase the desirable personality scores and to reduce undesirable scores in the treatment of patients with depressive disorder.

 
Keywords: Personality, Temperament, Character, Antidepressant drugs.
Full-Text [PDF 387 kb]   (2500 Downloads)    
Type of Study: Applicable | Subject: health management
Received: 2017/12/9 | Accepted: 2018/02/3 | Published: 2018/02/3
References
1. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry. 1993;50(12):975-90. [DOI:10.1001/archpsyc.1993.01820240059008] [PMID]
2. Malayeri N, Kaviani H, Asadi S, Hoseyni F. Evaluation of personality dimensions using the Cloninger Temperament and Character Inventory in subjects with borderline personality disorders. Tehran Med Sci J. 2008;66(9):633-8.
3. Hruby R, Nosalova G, Ondrejka I, Preiss M. Personality changes during antidepressant treatment. Psychiatr Danub. 2009;21(1):25-32. [PMID]
4. Fossati A, Cloninger CR, Villa D, Borroni S, Grazioli F, Giarolli L, et al. Reliability and validity of the Italian version of the Temperament and Character Inventory-Revised in an outpatient sample. Compr Psychiatry. 2007;48(4):380-7. [DOI:10.1016/j.comppsych.2007.02.003] [PMID]
5. Pournaghash Tehrani S. [Comparison of the effectiveness of methadone maintenance program on anxiety and depression symptoms of addicts]. J Psychol Stud. 2009;4(2):81-100.
6. Pournaghash Tehrani S, Nasri Tajabadi M, Yaghmaei F, Malekahmad M. [Comparison of Cognitive-emotional Dimensions of Personality in People with Psychiatric Disorders with Normal Individuals]. J Health Promot Manage. 2016;5(20):38-46.
7. Cloninger CR. A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatr Dev. 1986;4(3):167-226. [PMID]
8. Millon T, Millon C, Meagher S, Grossman S, Ramnath R. Personality Disorders in Modern Life. London: Wiley; 2004.
9. Hoseindoost F, Heshmati R. [Comparative study of temperament and character dimensions of personality in patients with major depressive disorder, bipolar I disorder and normal people]. Sci J Ilam Univ Med Sci. 2015;23(7):39-50.
10. Association AM. [Practical Guide to Depression Treatment]. Tehran: Savalan; 2010.
11. Sadock B, Sadock V. Kaplan and Sadock's Pocket Handbook of Clinical Psychiatry. 5th ed: Lippincott Williams & Wilkins; 2010.
12. Cloninger CR, Svrakic DM, Przybeck TR. Can personality assessment predict future depression? A twelve-month follow-up of 631 subjects. J Affect Disord. 2006;92(1):35-44. [DOI:10.1016/j.jad.2005.12.034] [PMID]
13. Hansenne M, Ansseau M. Harm avoidance and serotonin. Biol Psychol. 1999;51(1):77-81. [DOI:10.1016/S0301-0511(99)00018-6]
14. Birt M, Vaida A, Prelipceanu D. Use of the temperament and character inventory personality questionnaire in dysthymic disorder. Hi Educ. 2006;1(1):29-34.
15. Jylha P, Isometsa E. Temperament, character and symptoms of anxiety and depression in the general population. Eur Psychiatry. 2006;21(6):389-95. [DOI:10.1016/j.eurpsy.2005.09.003] [PMID]
16. Tome MB, Cloninger CR, Watson JP, Isaac MT. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. J Affect Disord. 1997;44(2-3):101-9. [DOI:10.1016/S0165-0327(97)00030-X]
17. Farmer A, Mahmood A, Redman K, Harris T, Sadler S, McGuffin P. A sib-pair study of the Temperament and Character Inventory scales in major depression. Arch Gen Psychiatry. 2003;60(5):490-6. [DOI:10.1001/archpsyc.60.5.490] [PMID]
18. Mochcovitch MD, Nardi AE, Cardoso A. Temperament and character dimensions and their relationship to major depression and panic disorder. Rev Bras Psiquiatr. 2012;34(3):342-51. [DOI:10.1016/j.rbp.2012.03.002] [PMID]
19. Joyce PR, Mulder RT, Cloninger CR. Temperament predicts clomipramine and desipramine response in major depression. J Affect Disord. 1994;30(1):35-46. [DOI:10.1016/0165-0327(94)90149-X]
20. Cloninger C, Thomas R, Dragan M, Richard D. The Temperament and Character Inventory (TCI): A guide to its development and use. St. Louis, MO: Center for Psychobiology of Personality, Washington University, 1994.
21. Kaneda A, Yasui-Furukori N, Nakagami T, Sato Y, Kaneko S. The influence of personality factors on paroxetine response time in patients with major depression. J Affect Disord. 2011;135(1-3):321-5. [DOI:10.1016/j.jad.2011.06.050] [PMID]
22. Garvey MJ, Noyes R, Cook B, Blum N. Preliminary confirmation of the proposed link between reward-dependence traits and norepinephrine. Psychiatry Res. 1996;65(1):61-4 [DOI:10.1016/0165-1781(96)02954-X]
23. Elovainio M, Kivimaki M, Steen N, Vahtera J. Job decision latitude, organizational justice and health: multilevel covariance structure analysis. Soc Sci Med. 2004;58(9):1659-69. [DOI:10.1016/S0277-9536(03)00366-6]
24. Fava M, Kendler KS. Major depressive disorder. Neuron. 2000;28(2):335-41. [DOI:10.1016/S0896-6273(00)00112-4]
25. Julien RM. A primer of drug action: A concise nontechnical guide to the actions, uses, and side effects of psychoactive drugs, revised and updated. New York: Worth Publishers; 2008.
26. Antelman SM, Caggiula AR. Norepinephrine-dopamine interactions and behavior. Science. 1977;195(4279):646-53. [DOI:10.1126/science.841304]
27. Sher KJ, Bartholow BD, Wood MD. Personality and substance use disorders: a prospective study. J Consult Clin Psychol. 2000;68(5):818-29. [DOI:10.1037/0022-006X.68.5.818] [PMID]
28. Daw ND, Kakade S, Dayan P. Opponent interactions between serotonin and dopamine. Neural Netw. 2002;15(4-6):603-16. [DOI:10.1016/S0893-6080(02)00052-7]
29. Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol. 2008;11 (5):625-39. [DOI:10.1017/S1461145707008383] [PMID]
30. Yıldız A, Gönül AS, Tamam L. Mechanism of actions of antidepressants: beyond the receptors. Bullet Clin Psychopharmacol. 2002;12(4):194-200.
31. Zald DH, Cowan RL, Riccardi P, Baldwin RM, Ansari MS, Li R, et al. Midbrain dopamine receptor availability is inversely associated with novelty-seeking traits in humans. J Neurosci. 2008;28 (53):14372-8. [DOI:10.1523/JNEUROSCI.2423-08.2008] [PMID] [PMCID]
32. Adan A, Serra-Grabulosa JM, Caci H, Natale V. A reduced Temperament and Character Inventory (TCI-56). Psychometric properties in a non-clinical sample. Pers Individ Differ. 2009;46(7):687-92. [DOI:10.1016/j.paid.2009.01.023]
33. Asnis GM, Wetzler S, Sanderson WC, Kahn RS, van Praag HM. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res. 1992;43(1):65-76. [DOI:10.1016/0165-1781(92)90142-P]
34. Borg J, Andree B, Soderstrom H, Farde L. The serotonin system and spiritual experiences. Am J Psychiatry. 2003;160(11):1965-9. [DOI:10.1176/appi.ajp.160.11.1965] [PMID]
35. Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2002;17(3):95-102. [DOI:10.1097/00004850-200205000-00001] [PMID]



XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 7, Issue 1 (Fedruary-March 2018) Back to browse issues page